1/ People wonder why $VERV moves faster clinically than $BEAM. The first reason it the FDA. They demand that each patient gets fully enrolled and treated one at a time in ex-vivo transplants before the next patient can even be enrolled.

2/ The second reason is many #CRISPR companies haven't even tried to deal with the FDA. $VERV tried and got jammed up with a hold. $NTLA still hasn't even tried for in the US. $BEAM is actually grinding its way through a real approval in the largest market in the world.

3/ For in-vivo liver patients, they will let them enroll and treat as many patients they want at one time. With the cell therapies each patient has to be completed through follow up before the next can go. This isn't $BEAM being slow or dragging its feet. Its FDA requirement.

4/ They are actually the only company since $CRSP to work their way through the rigorous process of getting approved by the FDA. That makes them a better management team then some of the more shady managements that skirt around the process.